FDA Reaffirms Benefit of Novartis’ MS Drug Gilenya Despite Fatality

Drug Industry Daily
A A
The FDA is reaffirming the benefits of Novartis’ multiple sclerosis (MS) drug Gilenya one week after the company confirmed that a patient died abruptly the day after starting treatment.

To View This Article:

Login

Subscribe To Drug Industry Daily